As drug products become more complex, developers are under increasing pressure to improve stability, reduce cold-chain reliance, and create innovative delivery formats that traditional manufacturing technologies struggle to support. While freeze drying remains the established approach for producing sterile dry powders, aseptic spray drying offers significant advantages in speed, scalability, cost efficiency, and particle engineering.
In this whitepaper, Dr Richard Johnson, Chief Scientific Officer at Upperton, examines the emerging role of aseptic spray drying in pharmaceutical development. Discover how the technology can enable high-concentration biologics, sustained-release formulations, and injectable powder suspensions, while also exploring the equipment, sterility, and powder handling challenges that must be overcome for successful implementation.
Download this whitepaper to learn:
- Why aseptic spray drying is gaining momentum as an alternative to freeze drying.
- The advantages of spray drying for speed, scalability, product consistency, and manufacturing efficiency.
- How spray drying supports emerging drug delivery platforms, including high-concentration biologics and injectable suspensions.
- The key technical challenges associated with sterile spray drying processes.
- Considerations for equipment design, aseptic processing, powder recovery, and sterile filling operations.